+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Lung Adenocarcinoma Treatment Market Size, Share & Trends Analysis Report by Treatment (Chemotherapy, Immunotherapy, Radiation Therapy), End-Use (Hospitals, Specialty Clinics), and Region (North America, Europe) with Growth Forecasts, 2025-2030

  • PDF Icon

    Report

  • 100 Pages
  • February 2025
  • Region: Global
  • Grand View Research
  • ID: 5998965
Description Jump to:
The Lung Adenocarcinoma Treatment Market was valued at USD 6.08 billion in 2024, and is projected to reach USD 11.18 billion by 2030, rising at a CAGR of 10.70%. This market offers a range of therapeutic options, technologies, and services aimed at managing and treating lung adenocarcinoma, which is a subtype of non-small cell lung cancer (NSCLC).

The rise in smoking rates in certain regions and environmental factors such as air pollution and occupational hazards are key growth drivers for market growth. As more individuals are diagnosed with lung adenocarcinoma, there is a corresponding demand for effective treatment options.

Increased awareness about lung cancer symptoms and risk factors has significantly influenced the market. Public health campaigns aimed at educating populations about smoking cessation and early detection led to more individuals seeking medical attention sooner after experiencing symptoms.

In October 2023, Bristol Myers Squibb acquired Mirati for USD 58.00 per share, totaling USD 4.8 billion in equity value, potentially rising to USD 5.8 billion with contingent value rights, including KRAZATI (adagrasib), a KRASG12C inhibitor for advanced non-small cell lung cancer.

Lung Adenocarcinoma Treatment Market Report Highlights

  • The chemotherapy segment accounted for the largest revenue share of 36% in 2024. This is primarily due to its established role in lung cancer management and ongoing advancements in treatment regimens.
  • The immunotherapy segment is expected to witness the fastest growth, with a projected CAGR of 13.5% over the forecast period. The rising prevalence of lung adenocarcinoma has increased the demand for advanced treatment options that offer better efficacy and safety compared to traditional therapies such as chemotherapy and radiation.
  • Hospitals accounted for the largest revenue share of 63.9% in 2024, driven by their comprehensive infrastructure and ability to provide a wide range of advanced cancer treatments.
  • The specialty clinics segment is expected to grow at the fastest CAGR over the forecast period. This growth is driven by the rising demand for personalized and targeted therapies, along with increasing patient awareness of lung cancer treatment options.
  • North America lung adenocarcinoma treatment market held the largest revenue share of 39.5% in 2024, driven by the rising incidence of lung adenocarcinoma and a strong focus on innovation in treatment approaches.

This report addresses:

  • Market intelligence to enable effective decision-making.
  • Market estimates and forecasts from 2018 to 2030.
  • Growth opportunities and trend analyses.
  • Segment and regional revenue forecasts for market assessment.
  • Competition strategy and market share analysis.
  • Product innovation listings for you to stay ahead of the curve.
  • COVID-19's impact and how to sustain in this fast-evolving market.

Why Should You Buy This Report?

  • Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This product will be delivered within 2 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Treatment
1.2.2. End use
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Lung Adenocarcinoma Treatment Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
3.3.3. Pipeline Analysis
Chapter 4. Lung adenocarcinoma treatment market: Type Business Analysis
4.1. Treatment Market Share, 2024 & 2030
4.2. Treatment Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Treatment, 2018 to 2030 (USD Million)
4.4. Chemotherapy
4.4.1. Chemotherapy Market, 2018-2030 (USD Million)
4.5. Targeted therapy
4.5.1. Targeted Therapy Market, 2018-2030 (USD Million)
4.6. Immunotherapy
4.6.1. Immunotherapy Market, 2018-2030 (USD Million)
4.7. Radiation therapy
4.7.1. Radiation Therapy Market, 2018-2030 (USD Million)
4.8. Other
4.8.1. Other Market, 2018-2030 (USD Million)
Chapter 5. Lung adenocarcinoma treatment market: End use Business Analysis
5.1. End Use Market Share, 2024 & 2030
5.2. End Use Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by End Use, 2018 to 2030 (USD Million)
5.4. Hospitals
5.4.1. Hospitals Market, 2018-2030 (USD Million)
5.5. Specialty Clinics
5.5.1. Specialty Clinics Market, 2018-2030 (USD Million)
5.6. Other
5.6.1. Other Market, 2018-2030 (USD Million)
Chapter 6. Lung adenocarcinoma treatment market: Regional Estimates & Trend Analysis
6.1. Regional Market Share Analysis, 2024 & 2030
6.2. Regional Market Dashboard
6.3. Market Size & Forecasts Trend Analysis, 2018 to 2030
6.4. North America
6.4.1. North America Lung Adenocarcinoma Treatment Market Estimates And Forecasts, by Country, 2018-2030 (USD Million)
6.4.2. U.S.
6.4.2.1. Key Country Dynamics
6.4.2.2. Regulatory Framework
6.4.2.3. Competitive Insights
6.4.2.4. U.S. Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018-2030 (USD Million)
6.4.3. Canada
6.4.3.1. Key Country Dynamics
6.4.3.2. Regulatory Framework
6.4.3.3. Competitive Insights
6.4.3.4. Canada Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018-2030 (USD Million)
6.4.4. Mexico
6.4.4.1. Key Country Dynamics
6.4.4.2. Regulatory Framework
6.4.4.3. Competitive Insights
6.4.4.4. Mexico Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018-2030 (USD Million)
6.5. Europe
6.5.1. Europe Lung Adenocarcinoma Treatment Market Estimates And Forecasts, by Country, 2018-2030 (USD Million)
6.5.2. UK
6.5.2.1. Key Country Dynamics
6.5.2.2. Regulatory Framework
6.5.2.3. Competitive Insights
6.5.2.4. UK Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018-2030 (USD Million)
6.5.3. Germany
6.5.3.1. Key Country Dynamics
6.5.3.2. Regulatory Framework
6.5.3.3. Competitive Insights
6.5.3.4. Germany Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018-2030 (USD Million)
6.5.4. France
6.5.4.1. Key Country Dynamics
6.5.4.2. Regulatory Framework
6.5.4.3. Competitive Insights
6.5.4.4. France Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018-2030 (USD Million)
6.5.5. Italy
6.5.5.1. Key Country Dynamics
6.5.5.2. Regulatory Framework
6.5.5.3. Competitive Insights
6.5.5.4. Italy Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018-2030 (USD Million)
6.5.6. Spain
6.5.6.1. Key Country Dynamics
6.5.6.2. Regulatory Framework
6.5.6.3. Competitive Insights
6.5.6.4. Spain Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018-2030 (USD Million)
6.5.7. Norway
6.5.7.1. Key Country Dynamics
6.5.7.2. Regulatory Framework
6.5.7.3. Competitive Insights
6.5.7.4. Norway Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018-2030 (USD Million)
6.5.8. Denmark
6.5.8.1. Key Country Dynamics
6.5.8.2. Regulatory Framework
6.5.8.3. Competitive Insights
6.5.8.4. Denmark Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018-2030 (USD Million)
6.5.9. Sweden
6.5.9.1. Key Country Dynamics
6.5.9.2. Regulatory Framework
6.5.9.3. Competitive Insights
6.5.9.4. Sweden Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018-2030 (USD Million)
6.6. Asia Pacific
6.6.1. Asia Pacific Lung Adenocarcinoma Treatment Market Estimates And Forecasts, by Country, 2018-2030 (USD Million)
6.6.2. Japan
6.6.2.1. Key Country Dynamics
6.6.2.2. Regulatory Framework
6.6.2.3. Competitive Insights
6.6.2.4. Japan Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018-2030 (USD Million)
6.6.3. China
6.6.3.1. Key Country Dynamics
6.6.3.2. Regulatory Framework
6.6.3.3. Competitive Insights
6.6.3.4. China Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018-2030 (USD Million)
6.6.4. India
6.6.4.1. Key Country Dynamics
6.6.4.2. Regulatory Framework
6.6.4.3. Competitive Insights
6.6.4.4. India Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018-2030 (USD Million)
6.6.5. South Korea
6.6.5.1. Key Country Dynamics
6.6.5.2. Regulatory Framework
6.6.5.3. Competitive Insights
6.6.5.4. South Korea Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018-2030 (USD Million)
6.6.6. Australia
6.6.6.1. Key Country Dynamics
6.6.6.2. Regulatory Framework
6.6.6.3. Competitive Insights
6.6.6.4. Australia Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018-2030 (USD Million)
6.6.7. Thailand
6.6.7.1. Key Country Dynamics
6.6.7.2. Regulatory Framework
6.6.7.3. Competitive Insights
6.6.7.4. Thailand Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018-2030 (USD Million)
6.7. Latin America
6.7.1. Latin America Lung Adenocarcinoma Treatment Market Estimates And Forecasts, by Country, 2018-2030 (USD Million)
6.7.2. Brazil
6.7.2.1. Key Country Dynamics
6.7.2.2. Regulatory Framework
6.7.2.3. Competitive Insights
6.7.2.4. Brazil Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018-2030 (USD Million)
6.7.3. Argentina
6.7.3.1. Key Country Dynamics
6.7.3.2. Regulatory Framework
6.7.3.3. Competitive Insights
6.7.3.4. Argentina Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018-2030 (USD Million)
6.8. MEA
6.8.1. MEA Lung Adenocarcinoma Treatment Market Estimates And Forecasts, by Country, 2018-2030 (USD Million)
6.8.2. South Africa
6.8.2.1. Key Country Dynamics
6.8.2.2. Regulatory Framework
6.8.2.3. Competitive Insights
6.8.2.4. South Africa Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018-2030 (USD Million)
6.8.3. Saudi Arabia
6.8.3.1. Key Country Dynamics
6.8.3.2. Regulatory Framework
6.8.3.3. Competitive Insights
6.8.3.4. Saudi Arabia Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018-2030 (USD Million)
6.8.4. UAE
6.8.4.1. Key Country Dynamics
6.8.4.2. Regulatory Framework
6.8.4.3. Competitive Insights
6.8.4.4. UAE Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018-2030 (USD Million)
6.8.5. Kuwait
6.8.5.1. Key Country Dynamics
6.8.5.2. Regulatory Framework
6.8.5.3. Competitive Insights
6.8.5.4. Kuwait Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018-2030 (USD Million)
Chapter 7. Competitive Landscape
7.1. Participant Overview
7.2. Company Market Position Analysis
7.3. Company Categorization
7.4. Strategy Mapping
7.5. Company Profiles/Listing
7.5.1. Pfizer Inc.
7.5.1.1. Overview
7.5.1.2. Financial Performance
7.5.1.3. Product Benchmarking
7.5.1.4. Strategic Initiatives
7.5.2. AstraZeneca
7.5.2.1. Overview
7.5.2.2. Financial Performance
7.5.2.3. Product Benchmarking
7.5.2.4. Strategic Initiatives
7.5.3. Bristol-Myers Squibb Company
7.5.3.1. Overview
7.5.3.2. Financial Performance
7.5.3.3. Product Benchmarking
7.5.3.4. Strategic Initiatives
7.5.4. Eli Lilly and Company
7.5.4.1. Overview
7.5.4.2. Financial Performance
7.5.4.3. Product Benchmarking
7.5.4.4. Strategic Initiatives
7.5.5. Boehringer Ingelheim International GmbH
7.5.5.1. Overview
7.5.5.2. Financial Performance
7.5.5.3. Product Benchmarking
7.5.5.4. Strategic Initiatives
7.5.6. Novartis AG
7.5.6.1. Overview
7.5.6.2. Financial Performance
7.5.6.3. Product Benchmarking
7.5.6.4. Strategic Initiatives
7.5.7. Merck KGaA (EMD Serono)
7.5.7.1. Overview
7.5.7.2. Financial Performance
7.5.7.3. Product Benchmarking
7.5.7.4. Strategic Initiatives
7.5.8. AbbVie Inc.
7.5.8.1. Overview
7.5.8.2. Financial Performance
7.5.8.3. Product Benchmarking
7.5.8.4. Strategic Initiatives
7.5.9. Astellas Pharma Inc.
7.5.9.1. Overview
7.5.9.2. Financial Performance
7.5.9.3. Product Benchmarking
7.5.9.4. Strategic Initiatives
7.5.10. F. Hoffmann-La Roche Ltd
7.5.10.1. Overview
7.5.10.2. Financial Performance
7.5.10.3. Product Benchmarking
7.5.10.4. Strategic Initiatives
List of Tables
Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 Global lung adenocarcinoma treatment market, by region, 2018-2030 (USD Million)
Table 4 Global lung adenocarcinoma treatment market, by treatment, 2018-2030 (USD Million)
Table 5 Global lung adenocarcinoma treatment market, by end use, 2018-2030 (USD Million)
Table 6 North America lung adenocarcinoma treatment market, by country, 2018-2030 (USD Million)
Table 7 North America lung adenocarcinoma treatment market, by treatment, 2018-2030 (USD Million)
Table 8 North America lung adenocarcinoma treatment market, by end use, 2018-2030 (USD Million)
Table 9 U.S. lung adenocarcinoma treatment market, by treatment, 2018-2030 (USD Million)
Table 10 U.S. lung adenocarcinoma treatment market, by end use, 2018-2030 (USD Million)
Table 11 Canada lung adenocarcinoma treatment market, by treatment, 2018-2030 (USD Million)
Table 12 Canada lung adenocarcinoma treatment market, by end use, 2018-2030 (USD Million)
Table 13 Mexico lung adenocarcinoma treatment market, by treatment, 2018-2030 (USD Million)
Table 14 Mexico lung adenocarcinoma treatment market, by end use, 2018-2030 (USD Million)
Table 15 Europe lung adenocarcinoma treatment market, by country, 2018-2030 (USD Million)
Table 16 Europe lung adenocarcinoma treatment market, by treatment, 2018-2030 (USD Million)
Table 17 Europe lung adenocarcinoma treatment market, by end use, 2018-2030 (USD Million)
Table 18 UK lung adenocarcinoma treatment market, by treatment, 2018-2030 (USD Million)
Table 19 UK lung adenocarcinoma treatment market, by end use, 2018-2030 (USD Million)
Table 20 Germany lung adenocarcinoma treatment market, by treatment, 2018-2030 (USD Million)
Table 21 Germany lung adenocarcinoma treatment market, by end use, 2018-2030 (USD Million)
Table 22 France lung adenocarcinoma treatment market, by treatment, 2018-2030 (USD Million)
Table 23 France lung adenocarcinoma treatment market, by end use, 2018-2030 (USD Million)
Table 24 Italy lung adenocarcinoma treatment market, by treatment, 2018-2030 (USD Million)
Table 25 Italy lung adenocarcinoma treatment market, by end use, 2018-2030 (USD Million)
Table 26 Spain lung adenocarcinoma treatment market, by treatment, 2018-2030 (USD Million)
Table 27 Spain lung adenocarcinoma treatment market, by end use, 2018-2030 (USD Million)
Table 28 Norway lung adenocarcinoma treatment market, by treatment, 2018-2030 (USD Million)
Table 29 Norway lung adenocarcinoma treatment market, by end use, 2018-2030 (USD Million)
Table 30 Denmark lung adenocarcinoma treatment market, by treatment, 2018-2030 (USD Million)
Table 31 Denmark lung adenocarcinoma treatment market, by end use, 2018-2030 (USD Million)
Table 32 Sweden lung adenocarcinoma treatment market, by treatment, 2018-2030 (USD Million)
Table 33 Sweden lung adenocarcinoma treatment market, by end use, 2018-2030 (USD Million)
Table 34 Asia Pacific lung adenocarcinoma treatment market, by country, 2018-2030 (USD Million)
Table 35 Asia Pacific lung adenocarcinoma treatment market, by treatment, 2018-2030 (USD Million)
Table 36 Asia Pacific lung adenocarcinoma treatment market, by end use, 2018-2030 (USD Million)
Table 37 Japan lung adenocarcinoma treatment market, by treatment, 2018-2030 (USD Million)
Table 38 Japan lung adenocarcinoma treatment market, by end use, 2018-2030 (USD Million)
Table 39 China lung adenocarcinoma treatment market, by treatment, 2018-2030 (USD Million)
Table 40 China lung adenocarcinoma treatment market, by end use, 2018-2030 (USD Million)
Table 41 India lung adenocarcinoma treatment market, by treatment, 2018-2030 (USD Million)
Table 42 India lung adenocarcinoma treatment market, by end use, 2018-2030 (USD Million)
Table 43 Australia lung adenocarcinoma treatment market, by treatment, 2018-2030 (USD Million)
Table 44 Australia lung adenocarcinoma treatment market, by end use, 2018-2030 (USD Million)
Table 45 South Korea lung adenocarcinoma treatment market, by treatment, 2018-2030 (USD Million)
Table 46 South Korea lung adenocarcinoma treatment market, by end use, 2018-2030 (USD Million)
Table 47 Thailand lung adenocarcinoma treatment market, by treatment, 2018-2030 (USD Million)
Table 48 Thailand lung adenocarcinoma treatment market, by end use, 2018-2030 (USD Million)
Table 49 Latin America lung adenocarcinoma treatment market, by country, 2018-2030 (USD Million)
Table 50 Latin America lung adenocarcinoma treatment market, by treatment, 2018-2030 (USD Million)
Table 51 Latin America lung adenocarcinoma treatment market, by end use, 2018-2030 (USD Million)
Table 52 Brazil lung adenocarcinoma treatment market, by treatment, 2018-2030 (USD Million)
Table 53 Brazil lung adenocarcinoma treatment market, by end use, 2018-2030 (USD Million)
Table 54 Argentina lung adenocarcinoma treatment market, by treatment, 2018-2030 (USD Million)
Table 55 Argentina lung adenocarcinoma treatment market, by end use, 2018-2030 (USD Million)
Table 56 Middle East & Africa lung adenocarcinoma treatment market, by country, 2018-2030 (USD Million)
Table 57 Middle East & Africa lung adenocarcinoma treatment market, by treatment, 2018-2030 (USD Million)
Table 58 Middle East & Africa lung adenocarcinoma treatment market, by end use, 2018-2030 (USD Million)
Table 59 South Africa lung adenocarcinoma treatment market, by treatment, 2018-2030 (USD Million)
Table 60 South Africa lung adenocarcinoma treatment market, by end use, 2018-2030 (USD Million)
Table 61 Saudi Arabia lung adenocarcinoma treatment market, by treatment, 2018-2030 (USD Million)
Table 62 Saudi Arabia lung adenocarcinoma treatment market, by end use, 2018-2030 (USD Million)
Table 63 UAE lung adenocarcinoma treatment market, by treatment, 2018-2030 (USD Million)
Table 64 UAE lung adenocarcinoma treatment market, by end use, 2018-2030 (USD Million)
Table 65 Kuwait lung adenocarcinoma treatment market, by treatment, 2018-2030 (USD Million)
Table 66 Kuwait lung adenocarcinoma treatment market, by end use, 2018-2030 (USD Million)
List of Figures
Figure 1 Lung Adenocarcinoma Treatment Market segmentation
Figure 2 Market research process
Figure 3 Data triangulation techniques
Figure 4 Primary research pattern
Figure 5 Market research approaches
Figure 6 Value-chain-based sizing & forecasting
Figure 7 Market formulation & validation
Figure 8 Market snapshot
Figure 9 Treatment and end use outlook (USD Million)
Figure 10 Competitive landscape
Figure 11 Lung adenocarcinoma treatment market dynamics
Figure 12 Lung adenocarcinoma treatment market: Porter’s five forces analysis
Figure 13 Lung adenocarcinoma treatment market: PESTLE analysis
Figure 14 Lung adenocarcinoma treatment market: Treatment segment dashboard
Figure 15 Lung adenocarcinoma treatment market: Treatment market share analysis, 2024 & 2030
Figure 16 Chemotherapy market, 2018-2030 (USD Million)
Figure 17 Targeted therapy market, 2018-2030 (USD Million)
Figure 18 Immunotherapy market, 2018-2030 (USD Million)
Figure 19 Radiation therapy market, 2018-2030 (USD Million)
Figure 20 Other market, 2018-2030 (USD Million)
Figure 21 Lung adenocarcinoma treatment market: End use segment dashboard
Figure 22 Lung adenocarcinoma treatment market: End use market share analysis, 2024 & 2030
Figure 23 Hospitals market, 2018-2030 (USD Million)
Figure 24 Specialty clinics market, 2018-2030 (USD Million)
Figure 25 Other market, 2018-2030 (USD Million)
Figure 26 Lung Adenocarcinoma Treatment Market revenue, by region
Figure 27 Regional marketplace: Key takeaways
Figure 28 North America lung adenocarcinoma treatment market, 2018-2030 (USD Million)
Figure 29 U.S. country dynamics
Figure 30 U.S. lung adenocarcinoma treatment market, 2018-2030 (USD Million)
Figure 31 Canada country dynamics
Figure 32 Canada lung adenocarcinoma treatment market, 2018-2030 (USD Million)
Figure 33 Mexico country dynamics
Figure 34 Mexico lung adenocarcinoma treatment market, 2018-2030 (USD Million)
Figure 35 Europe lung adenocarcinoma treatment market, 2018-2030 (USD Million)
Figure 36 UK country dynamics
Figure 37 UK lung adenocarcinoma treatment market, 2018-2030 (USD Million)
Figure 38 Germany country dynamics
Figure 39 Germany lung adenocarcinoma treatment market, 2018-2030 (USD Million)
Figure 40 France country dynamics
Figure 41 France lung adenocarcinoma treatment market, 2018-2030 (USD Million)
Figure 42 Italy country dynamics
Figure 43 Italy lung adenocarcinoma treatment market, 2018-2030 (USD Million)
Figure 44 Spain country dynamics
Figure 45 Spain lung adenocarcinoma treatment market, 2018-2030 (USD Million)
Figure 46 Norway country dynamics
Figure 47 Norway lung adenocarcinoma treatment market, 2018-2030 (USD Million)
Figure 48 Sweden country dynamics
Figure 49 Sweden lung adenocarcinoma treatment market, 2018-2030 (USD Million)
Figure 50 Denmark country dynamics
Figure 51 Denmark lung adenocarcinoma treatment market, 2018-2030 (USD Million)
Figure 52 Asia Pacific lung adenocarcinoma treatment market, 2018-2030 (USD Million)
Figure 53 Japan country dynamics
Figure 54 Japan lung adenocarcinoma treatment market, 2018-2030 (USD Million)
Figure 55 China country dynamics
Figure 56 China lung adenocarcinoma treatment market, 2018-2030 (USD Million)
Figure 57 India country dynamics
Figure 58 India lung adenocarcinoma treatment market, 2018-2030 (USD Million)
Figure 59 Australia country dynamics
Figure 60 Australia lung adenocarcinoma treatment market, 2018-2030 (USD Million)
Figure 61 South Korea country dynamics
Figure 62 South Korea lung adenocarcinoma treatment market, 2018-2030 (USD Million)
Figure 63 Thailand country dynamics
Figure 64 Thailand lung adenocarcinoma treatment market, 2018-2030 (USD Million)
Figure 65 Latin America lung adenocarcinoma treatment market, 2018-2030 (USD Million)
Figure 66 Brazil country dynamics
Figure 67 Brazil lung adenocarcinoma treatment market, 2018-2030 (USD Million)
Figure 68 Argentina country dynamics
Figure 69 Argentina lung adenocarcinoma treatment market, 2018-2030 (USD Million)
Figure 70 MEA lung adenocarcinoma treatment market, 2018-2030 (USD Million)
Figure 71 South Africa country dynamics
Figure 72 South Africa lung adenocarcinoma treatment market, 2018-2030 (USD Million)
Figure 73 Saudi Arabia country dynamics
Figure 74 Saudi Arabia lung adenocarcinoma treatment market, 2018-2030 (USD Million)
Figure 75 UAE country dynamics
Figure 76 UAE lung adenocarcinoma treatment market, 2018-2030 (USD Million)
Figure 77 Kuwait country dynamics
Figure 78 Kuwait lung adenocarcinoma treatment market, 2018-2030 (USD Million)
Figure 79 Company categorization
Figure 80 Company market position analysis
Figure 81 Strategic framework

Companies Mentioned

The major companies profiled in this Lung Adenocarcinoma Treatment market report include:
  • Pfizer Inc.
  • AstraZeneca
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Boehringer Ingelheim International GmbH
  • Novartis AG
  • Merck KGaA (EMD Serono)
  • AbbVie Inc.
  • Astellas Pharma Inc.
  • F. Hoffmann-La Roche Ltd

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages100
PublishedFebruary 2025
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 6.08 Billion
Forecasted Market Value ( USD ) by 2030 $ 11.18 Billion
Compound Annual Growth Rate10.7%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Metastatic Lung Adenocarcinoma Treatment Market Size, Share & Trends Analysis Report by Treatment (Chemotherapy, Targeted Therapy), End Use (Hospitals, Specialty Clinics), and Region with Growth Forecasts, 2025-2030 - Product Image

Metastatic Lung Adenocarcinoma Treatment Market Size, Share & Trends Analysis Report by Treatment (Chemotherapy, Targeted Therapy), End Use (Hospitals, Specialty Clinics), and Region with Growth Forecasts, 2025-2030

  • Report
  • 120 Pages
  • Global
From
Lung Adenocarcinoma - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Lung Adenocarcinoma - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Lung Adenocarcinoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 - Product Image

Lung Adenocarcinoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

  • Report
  • 129 Pages
  • Global
From
Lung Adenocarcinoma Market Report and Forecast 2024-2032 - Product Image

Lung Adenocarcinoma Market Report and Forecast 2024-2032

  • Report
  • 160 Pages
  • Global
From
Non-Small Cell Lung Cancer Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Non-Small Cell Lung Cancer Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 183 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.